Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study

Abstract

During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational cohort study evaluating safety and ef ficacy. Adults receiving ibrutinib with or without rituximab for untreated MCL were evaluated for treatment toxicity, response, and survival, including outcomes in high -risk MCL ( TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, or Ki67 >= 30%). A total of 149 patients from 43 participating centers were enrolled: 74.1% male, median age 75 years, 75.2% Eastern Cooperative Oncology Group status of 0 to 1, 36.2% high -risk, and 8.9% autologous transplant candidates. All patients received >= 1 cycle ibrutinib (median, 8 cycles), 39.0% with rituximab. Grade >= 3 toxicity occurred in 20.3%, and 33.8% required dose reductions/delays. At 15.6-month median followup, 41.6% discontinued ibrutinib, 8.1% due to toxicity. Of 104 response-assessed patients, overall (ORR) and complete response (CR) rates were 71.2% and 20.2%, respectively. ORR was 77.3% (low risk) vs 59.0% (high risk) ( P = .05) and 78.7% (ibrutinib-rituximab) vs 64.9% (ibrutinib; P = .13). Median progression -free survival (PFS) was 26.0 months (all patients); 13.7 months (high risk) vs not reached (NR) (low risk; hazard ratio [HR], 2.19; P = .004). Median overall survival was NR (all); 14.8 months (high risk) vs NR (low risk; HR, 2.36; P = .005). Median post-ibrutinib survival was 1.4 months, longer in 41.9% patients receiving subsequent treatment (median, 8.6 vs 0.6 months; HR, 0.36; P = .002). Ibrutinib with or without rituximab was effective and well tolerated as first -line treatment of MCL, including older and transplant -ineligible patients. PFS and OS were signi ficantly inferior in one-third of patients with high -risk disease and those unsuitable for post-ibrutinib treatment, highlighting the need for novel approaches in these groups.